Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Midodrine vs Pyridostigmine for Neurogenic Orthostatic Hypotension
NCT02308124Phase 4Completed
- Sponsor
- Seoul National University Hospital
- Start
- Nov 2014
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of midodrine and pyridostigmine in Neurogenic Orthostatic Hypotension (nOH) (3 arms), sponsored by Seoul National University Hospital. Primary endpoint: Change in Orthostatic Blood Pressure Drop at 3 months. Started Nov 2014; status: completed.
02
Drugs
midodrinepyridostigmine
03
Conditions
Neurogenic Orthostatic Hypotension (nOH)
Beyond the preview
Go deeper on NCT02308124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02308124.